Drug Information Association 2013: Aptiv Solutions Experts to Present on Optimizing Pipelines With Adaptive Trial Designs, Medical Device Human Factors, and Fundamental Changes in Statistics for Drug Development

Published: Jun 24, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RESTON, Va.--(BUSINESS WIRE)--Aptiv Solutions, a global biopharmaceutical and medical device development services company and leader in adaptive clinical trials, will present at three symposia at DIA 2013, the annual conference of the Drug Information Association, held at the Boston Convention and Exhibition Center, June 23-27. Adopting an Adaptive Design Strategy to Manage Portfolio Risk and Value Monday June 24, 2013 from 11:00 a.m. to 12:30 p.m.; Room 104C Sarah Arbe-Barnes, Ph.D., Senior Vice President Translational Research, will discuss the benefits of adopting an adaptive design strategy across a product portfolio in the Portfolio Management Symposium. In May, the Tufts Center for the Study of Drug Development published a report that demonstrated $100 to $200 million in savings from portfolio-level application of adaptive designs. The study found that more than 20% of clinical trials now employ adaptive designs and indicated further growth.

Help employers find you! Check out all the jobs and post your resume.

Back to news